ASH 2023 | The impact of salvage and bridging therapy on CAR T-cell therapy outcomes in B-ALL: an ITT analysis
Valentín Ortiz-Maldonado, MD, Hospital Clinic Barcelona, Barcelona, Spain, discusses the findings of an intention-to-treat (ITT) analysis investigating the impact of salvage and bridging therapy in patients with refractory B-cell acute lymphoblastic leukemia (B-ALL) who were referred for anti-CD19 CAR T-cell therapy. This analysis determined that the sensitivity and responsiveness of the tumor to the salvage and bridging therapy, not the tumor burden, affected the survival outcomes of patients. Dr Ortiz-Maldonado emphasizes the need to carefully consider which salvage and bridging therapy is used, as the effect on the proliferative kinetics of the disease will affect the efficacy of the subsequent CAR T-cell therapy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Pfizer, Miltenyi Biomedicine, Celgene BMS, Kite, Janssen, Novartis
Honoraria: Celgene BMS, Kite, Janssen
